Inovio Phase 1 Data of INO-4800 for COVID-19
Peer-reviewed Phase 1 data shows Inovio COVID-19 DNA Vaccine Candidate, INO-4800, to be immunogenic in 100% of subjects, inducing neutralizing antibody and/or T cell responses.
- INO-4800 demonstrates favorable safety and tolerability.
- No serious adverse events reported.
- Offers best-in-class thermostability, including a five-year projected shelf life at normal refrigeration temperature and no frozen transport or storage requirements.
